BD ONCLARITY TM HPV ASSAY
BD Onclarity™ HPV Assay detects all 14 of the high-risk HPV genotypes, including types 16 and 18, which contribute to 70% of cervical cancers. As more women are vaccinated against HPV, the prevalence of types 16 and 18 have declined. HPV 31 has a higher risk for pre-cervical cancer than HPV 18, however, and can go undetected. Unlike other cervical cancer assays, BD Onclarity™ HPV Assay does not pool HPV 31 with other types of HPV, allowing clinicians to individually detect high-risk HPV-31. The BD Onclarity™ HPV Assay gives clinicians the ability to identify a woman’s risk more precisely for developing cervical pre-cancer and cancer, and therefore, manage better outcomes for patients, says the manufacturer.
FOR MORE INFORMATION, VISIT: https://womens-health-solutions.bd.com/
